WO2011027348A1 - Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis - Google Patents
Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis Download PDFInfo
- Publication number
- WO2011027348A1 WO2011027348A1 PCT/IL2010/000729 IL2010000729W WO2011027348A1 WO 2011027348 A1 WO2011027348 A1 WO 2011027348A1 IL 2010000729 W IL2010000729 W IL 2010000729W WO 2011027348 A1 WO2011027348 A1 WO 2011027348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meca
- psoriasis
- pharmaceutical composition
- treatment
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- This invention relates to the treatment of psoriasis.
- the A 3 adenosine receptor a Gi protein-associated cell surface receptor
- the receptor is highly expressed in various tumor cell types while expression in adjacent normal tissues is relatively low.
- Activation of the receptor by a specific synthetic agonist induces modulation of downstream signal transduction pathways which include the Wnt and the NF-kB, resulting in tumor growth inhibition (1-5).
- a 3 adenosine receptor (A 3 AR) agonists inhibit the development of colon, prostate and pancreatic carcinomas as well as melanoma and hepatoma.
- a 3 AR agonists were also been shown to act as anti-inflammatory agents by ameliorating the inflammatory process in different experimental autoimmune models such as rheumatoid arthritis, Crohn's disease and multiple sclerosis (6-10).
- the A 3 AR was found to be highly expressed in inflammatory tissues (synovia and paw) derived from adjuvant (AIA) and collagen induced arthritis experimental models (11). This over expression was reflected in the PBMNC of the animals.
- Psoriasis is a chronic condition. People often experience flares and remissions throughout their life.
- psoriasis There are several forms of psoriasis, and each form has unique characteristics that allow dermatologists to visually identify psoriasis to determine what type, or types, of psoriasis is present. Sometimes a skin biopsy will be performed to confirm the diagnosis.
- the main types of psoriasis include the following:
- Plaque Psoriasis redened areas a few inches across covered by silvery scales
- Pustular Psoriasis blisters of noninfectious pus on red skin
- Erythroderma Psoriasis reddening and scaling of most of the skin.
- Psoriasis treatments fall into 3 categories:
- Topical (applied to the skin); - Mild to moderate psoriasis;
- Phototherapy (light, usually ultraviolet, applied to the skin) - Moderate to severe psoriasis;
- the treatment options can clear psoriasis for a period of time.
- Each treatment has advantages and disadvantages, and what works for one patient may not be effective for another.
- CF101 methyl 1-[N 6 - (3-iodobenzyl)-adenin-9-yl]-p-D-ribofuronamide, IB-MECA, an A 3 AR agonist
- IB-MECA an A 3 AR agonist
- the present invention is based on the clinical finding that oral administration of IB-MECA to subjects having moderate to severe psoriasis, in daily dose of 4mg (twice daily administration of 2 mg) was significantly more effective in treatment of the psoriatic plaques than treatment of psoriasis at daily doses of 2 mg or 8 mg.
- the present disclosure provides a pharmaceutical composition, e.g. in dosage form, for the treatment of psoriasis comprising as an active ingredient l-[N 6 -(3- iodobenzyl)-adenin-9-yl]-P-D-ribofuronamide (IB-MECA) in an amount suitable for a total daily dose of about 4mg.
- a pharmaceutical composition e.g. in dosage form, for the treatment of psoriasis comprising as an active ingredient l-[N 6 -(3- iodobenzyl)-adenin-9-yl]-P-D-ribofuronamide (IB-MECA) in an amount suitable for a total daily dose of about 4mg.
- the term "daily dose” should be understood to encompass the amount of the active ingredient, namely, IB-MECA being administered per day to the subject in need thereof.
- the daily dose may encompass a single daily administration or more than one administrations per day, as long as the total amount of IB-MECA received by the subject per day is about 4mg.
- the pharmaceutical composition may formulated for a single daily administration, in which case the amount of IB-MECA in the composition is about 4 mg, or for administration twice a day, in which case the amount of IB-MECA is about 2 mg.
- the composition may be formulated for 3- or 4-times daily administration in which case the dosage form will comprise, respectively, about 1.33 and 1 mg of IB-MECA.
- the present disclosure also provides IB-MECA for use in the treatment of psoriasis, the IB-MECA being administered to a subject having psoriasis in a total daily dose of about 4 mg.
- a method of treatment of psoriasis comprising administering to a subject having psoriasis IB-MECA at a total daily dose of about 4 mg.
- a package comprising IB-MECA or a pharmaceutical composition comprising IB-MECA and instructions for use of IB-MECA or the composition comprising the same for the treatment of a patient having psoriasis with a 4 mg daily amount of IB-MECA.
- Fig. 1 is a graph showing the change in the Psoriasis Area and Severity Index (PASI) score from baseline over the study period of the 2 mg IB-MECA group (CF101) versus placebo.
- PASI Psoriasis Area and Severity Index
- Fig. 2 is a histogram showing the difference between three doses of IB-MECA (lmg, 2mg and 4mg) in the change in the PASI score from baseline over the study period.
- the present invention is based on clinical trials in psoriasis patients where the effect of IB-MECA in ameliorating disease symptoms in psoriasis patients was tested.
- the study results demonstrated a marked effect of 2 mg dose of IB-MECA, administered twice daily (namely a total daily dose of 4 mg) in ameliorating disease manifestation in these patients.
- a daily dose of 4 mg is superior to a lower daily dose of 2 mg or a higher dose of 8 mg.
- psoriasis encompass any form of psoriasis including, without being limited thereto, plaque psoriasis; pustular psoriasis (including arthritic psoriasis or psoriatic arthritis); Guttate psoriasis; inverse or flexural psoriasis; erythroderma psoriasis. Further, in the context of the present invention, when referring to "psoriasis” it is meant to include any degree of psoriasis, including, mild, moderate and severe psoriasis.
- treatment includes any improvement in one or more objective parameters that are used to assess a psoriatic state (severity) in clinical trials, namely redness, thickness and scalliness of psoriatic lesions. Based on these parameters, several tools for assessing the effectiveness of treatment of psoriasis have been developed.
- the assessment tools include traditional assessment tools such as the Psoriasis Area and Severity Index (PASI), the Physician Global Assessment (PGA), as well as more recent assessment tools, such as the National Psoriasis Foundation Psoriasis Score (NPF-PS), the Physical Static Global Assessment (PSGA) and Overall Lesion Assessment (OLA) [S.R. Feldman and G.G.Krueger Psoriasis assessment tools in clinical trials, Ann Rheum. Dis. 64 (Suppl. II):ii65-ii68 (2005)].
- PESI Psoriasis Area and Severity Index
- PGA Physician Global Assessment
- OPA Overall Lesion Assessment
- PASI and PGA are the two most commonly used tools in assessing psoriasis activity and in following clinical response to treatment.
- the PASI assessment tool evaluates the degree of erythema, thickness and scaling of psoriatic plaques and estimates the extent of involvement of each of these components in four separate body areas (head, trunk, upper and lower extremities).
- the PASI composite score ranging from 0-72.
- the PGA assessment tool is a six point score that summarizes the overall erythema, scaling, and thickness and the extend of plaques relative to a baseline assessment, the scores including worse, poor (0-24%), fair (25-49%), good (50-74%), excellent (75-99%) and cleared (100%). [Alice B Gottlieb et al. The National Psoriasis Foundation Psoriasis Score System versus the Psoriasis Area Severity Index and Physician 's Glogal Assessment: a comparison, Journal of Drugs in Dermatology June 2003].
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient IB-MECA, the use of IB-MECA in treatment and a method for treatment of psoriasis, the composition, use and method being characterized in that the active ingredient, i.e. IB-MECA is administered to achieve a total daily dose of about 4 mg.
- the active ingredient namely, IB-MECA
- the composition may be formulated for nasal administration, may be in the form of an inhaled formulation, may in the form of a suppository or may even be formulated for parenteral administration.
- Oral administration in the context of the present invention, includes any one of (a) liquid solutions, such as an effective amount of IB-MECA dissolved in diluents, such as water, saline or even orange juice; (b) solid and semi solid forms; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
- IB-MECA will typically be formulated in a dosage for suitable to achieve the desired daily dose of 4mg.
- Liquid forms may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
- diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
- Solid forms which are a preferred administration form in the context of the invention, may include, without being limited thereto, pills, tablets, including immediate and modified (controlled) release tablets, uncoated and coated tablets (including enteric coating), chewable tablets, bi or multi layer tablets; pellets; capsules, including soft gelatin gel capsules and hard shelled gelatin capsules; powders including granules and oral powders for reconstitution, lozenges, cachets.
- the capsules may include, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch.
- the tablets may include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodiumk talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
- the lozenges may comprise IB-MECA in a flavor, such as sucrose and acacia or tragacanth, as well as pastilles comprising IB-MECA in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to IB-MECA, such carriers as are known in the art.
- a flavor such as sucrose and acacia or tragacanth
- pastilles comprising IB-MECA in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to IB-MECA, such carriers as are known in the art.
- the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient so as to facilitate oral delivery of IB-MECA.
- the pharmaceutical composition is in the form of a tablet.
- a tablet may be made by compression or molding, optionally with one or more of said excipients.
- Compressed tablets may be prepared by compressing in a suitable machine IB-MECA in a free-flowing form, e.g., a powder or granules, optionally mixed with the excipient(s), e.g., binders, lubricants, inert diluents, surface active or dispersing agents.
- Molded tablets may be made by molding in a suitable machine, a mixture of the powdered IB-MECA with any suitable carier.
- the tablet includes the components shown Table 1 provided hereinafter in the description of a non-limiting example.
- IB-MECA may be administered once, twice or several times a day. In one embodiment, IB-MECA is administered once a day, the dosage form including about 4 mg of IB-MECA. In another embodiment, IB-MECA is administered twice a day, each administration dosage form including about 2 mg of IB-MECA (to achieve the total daily amount of 4mg) protest
- the present disclosure also provide the use of IB-MECA in the treatment or in the preparation of a pharmaceutical composition for the treatment of psoriasis, the administration dose being formulated in a form suitable for a daily administration of about 4 mg of IB-MECA.
- the present disclosure provides IB-MECA for use in the treatment of psoriasis, said IB-MECA being administered to a subject having psoriasis in a daily dose amount of about 4 mg.
- a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study was conducted in adult males and females, with ages of 18 to 70 years, with a diagnosis of moderate-to-severe chronic plaque psoriasis.
- Electrocardiogram is normal or shows abnormalities which, in the judgment of the Investigator, are not clinically significant
- Females of child-bearing potential must have a negative serum pregnancy test at screening; Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example oral
- contraceptive pills plus a barrier method to be eligible for, and continue participation in, the study;
- Treatment with high potency topical corticosteroids (Class I-III), keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;
- UV or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;
- Treatment with a biological agent including etanercept, adalimumab, efalizumab, infliximab, or alefacept
- a biological agent including etanercept, adalimumab, efalizumab, infliximab, or alefacept
- WBC White blood cell
- Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal
- IB-MECA clinical grade l-[N 6 -(3-iodobenzyl)-adenin-9-yl]- -D-ribofuronamide
- IB-MECA code-named by the study sponsor, Can-Fite Biopharma, the Assignee of this application, as "CF101"
- IB-MECA was formulated in a tablet formulation as detailed in Table 1 below. Patients were instructed to take the formulation on an empty stomach. The study duration was 12 weeks.
- Cohort 1 1 mg IB-MECA or placebo.
- Cohort 2 2 mg IB-MECA or placebo.
- Cohort 3 4 mg IB-MECA or placebo.
- Psoriasis Area and Severity Index Psoriasis Area and Severity Index
- Placebo 15 patients One mg IB-MECA: 14 patients
- Fig. 1 shows the change in the PASI score from baseline over the study period of the total 4 mg IB-MECA group (3mg administered twice a day) versus placebo, demonstrating a continuous improvement in the patients' condition throughout the course of the study in the 4 mg IB-MECA group without or very little change in the placebo group.
- the 2 mg dose group (total of 4 mg/day) of IB-MECA had a profound and previously unexpected advantage in generating a considerably greater response over the two other tested dose groups.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10763456.0A EP2475371B1 (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis |
JP2012527447A JP5758896B2 (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition comprising an A3 adenosine receptor agonist (IB-MECA / CF-101) for the treatment of psoriasis |
ES10763456.0T ES2616882T3 (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition comprising an adenosine A3 receptor agonist (IB-MECA / CF-101) for the treatment of psoriasis |
US13/394,373 US8987228B2 (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis |
KR1020127004156A KR101741281B1 (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis |
CN2010800392421A CN102481308A (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition comprising A3 adenosine receptor agonist (IB-MECA/CF-101) for treatment of psoriasis |
DK10763456.0T DK2475371T3 (en) | 2009-09-06 | 2010-09-06 | PHARMACEUTICAL COMPOSITION COMPREHENSIVE A3-ADENOSIN RECEPTOR AGONIST (IB-MECA / CF-101) FOR TREATMENT OF PSORIASIS |
IN2729DEN2012 IN2012DN02729A (en) | 2009-09-06 | 2012-03-29 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL200753A IL200753A (en) | 2009-09-06 | 2009-09-06 | Pharmaceutical composition comprising ib-meca for the treatment of psoriasis |
IL200753 | 2009-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011027348A1 true WO2011027348A1 (en) | 2011-03-10 |
Family
ID=42335564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2010/000729 WO2011027348A1 (en) | 2009-09-06 | 2010-09-06 | Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis |
Country Status (11)
Country | Link |
---|---|
US (1) | US8987228B2 (en) |
EP (1) | EP2475371B1 (en) |
JP (1) | JP5758896B2 (en) |
KR (1) | KR101741281B1 (en) |
CN (2) | CN104173364A (en) |
DK (1) | DK2475371T3 (en) |
ES (1) | ES2616882T3 (en) |
HK (1) | HK1204764A1 (en) |
IL (1) | IL200753A (en) |
IN (1) | IN2012DN02729A (en) |
WO (1) | WO2011027348A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987228B2 (en) | 2009-09-06 | 2015-03-24 | Can-Fite Biopharma Ltd. | Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis |
WO2024003911A1 (en) * | 2022-06-29 | 2024-01-04 | Can-Fite Biopharma Ltd. | Pharmaceutical composition comprising a3 adenosine receptor agonist for treatment of psoriasis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019045182A1 (en) | 2017-08-31 | 2019-03-07 | 주식회사 이뮨메드 | Composition for preventing and treating skin disorders including material which specifically binds to vimentin-derived peptide |
IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in treatment |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040016709A1 (en) | 2001-06-04 | 2004-01-29 | Chris Felcman | System and method for mounting a keyboard and display assembly in a 1U rack space |
WO2004045627A1 (en) | 2002-11-19 | 2004-06-03 | Can-Fite Biopharma Ltd. | A3ar agonists for the treatment of inflammatory arthritis |
WO2005063246A1 (en) | 2003-12-29 | 2005-07-14 | Can-Fite Biopharma Ltd. | Method for treatment of multiple sclerosis |
WO2006059327A1 (en) * | 2004-12-02 | 2006-06-08 | Can-Fite Biopharma Ltd. | A biological marker for inflammation |
WO2008056361A1 (en) | 2006-11-09 | 2008-05-15 | Can-Fite Biopharma Ltd. | A biological marker for psoriasis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
EP1305023A4 (en) * | 2000-08-01 | 2005-02-23 | Univ Virginia | Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
IL184620A0 (en) * | 2007-07-15 | 2008-01-20 | Can Fite Biopharma Ltd | Composition for the treatment of inflammation |
IL200753A (en) | 2009-09-06 | 2015-06-30 | Can Fite Biopharma Ltd | Pharmaceutical composition comprising ib-meca for the treatment of psoriasis |
-
2009
- 2009-09-06 IL IL200753A patent/IL200753A/en active IP Right Grant
-
2010
- 2010-09-06 EP EP10763456.0A patent/EP2475371B1/en active Active
- 2010-09-06 CN CN201410341997.7A patent/CN104173364A/en active Pending
- 2010-09-06 DK DK10763456.0T patent/DK2475371T3/en active
- 2010-09-06 WO PCT/IL2010/000729 patent/WO2011027348A1/en active Application Filing
- 2010-09-06 KR KR1020127004156A patent/KR101741281B1/en active IP Right Grant
- 2010-09-06 US US13/394,373 patent/US8987228B2/en active Active
- 2010-09-06 JP JP2012527447A patent/JP5758896B2/en active Active
- 2010-09-06 ES ES10763456.0T patent/ES2616882T3/en active Active
- 2010-09-06 CN CN2010800392421A patent/CN102481308A/en active Pending
-
2012
- 2012-03-29 IN IN2729DEN2012 patent/IN2012DN02729A/en unknown
-
2015
- 2015-06-02 HK HK15105261.4A patent/HK1204764A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040016709A1 (en) | 2001-06-04 | 2004-01-29 | Chris Felcman | System and method for mounting a keyboard and display assembly in a 1U rack space |
WO2004045627A1 (en) | 2002-11-19 | 2004-06-03 | Can-Fite Biopharma Ltd. | A3ar agonists for the treatment of inflammatory arthritis |
WO2005063246A1 (en) | 2003-12-29 | 2005-07-14 | Can-Fite Biopharma Ltd. | Method for treatment of multiple sclerosis |
WO2006059327A1 (en) * | 2004-12-02 | 2006-06-08 | Can-Fite Biopharma Ltd. | A biological marker for inflammation |
WO2008056361A1 (en) | 2006-11-09 | 2008-05-15 | Can-Fite Biopharma Ltd. | A biological marker for psoriasis |
Non-Patent Citations (13)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987228B2 (en) | 2009-09-06 | 2015-03-24 | Can-Fite Biopharma Ltd. | Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis |
WO2024003911A1 (en) * | 2022-06-29 | 2024-01-04 | Can-Fite Biopharma Ltd. | Pharmaceutical composition comprising a3 adenosine receptor agonist for treatment of psoriasis |
Also Published As
Publication number | Publication date |
---|---|
EP2475371B1 (en) | 2016-11-23 |
IN2012DN02729A (en) | 2015-09-11 |
DK2475371T3 (en) | 2017-03-06 |
IL200753A0 (en) | 2010-06-30 |
HK1204764A1 (en) | 2015-12-04 |
CN102481308A (en) | 2012-05-30 |
EP2475371A1 (en) | 2012-07-18 |
JP5758896B2 (en) | 2015-08-05 |
CN104173364A (en) | 2014-12-03 |
US20120165284A1 (en) | 2012-06-28 |
ES2616882T3 (en) | 2017-06-14 |
US8987228B2 (en) | 2015-03-24 |
IL200753A (en) | 2015-06-30 |
JP2013503851A (en) | 2013-02-04 |
KR20120067994A (en) | 2012-06-26 |
KR101741281B1 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170151200A1 (en) | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies | |
US8987228B2 (en) | Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis | |
US7713984B2 (en) | Pharmaceutical uses | |
JPH10504839A (en) | How to reduce the risk of non-vertebral fracture | |
TW201016208A (en) | Methods of treatment of hyperuricemia and associated disease states | |
JP2020523334A (en) | Vibegron dosing for the treatment of overactive bladder | |
TW201817425A (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
WO2022253034A1 (en) | Use of pyrrolopyrimidine compound | |
KR20140044816A (en) | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder | |
Fishman et al. | Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N 6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide (IB-MECA/CF-101) for treatment of psoriasis | |
CN104224788A (en) | Medicinal composition of indapamide and folic acid and application of medicinal composition | |
AU2017245302A1 (en) | Pharmaceutical combinations | |
Van der Does et al. | Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide | |
WO2024003911A1 (en) | Pharmaceutical composition comprising a3 adenosine receptor agonist for treatment of psoriasis | |
JP2020527156A (en) | Use of cladribine to treat autoimmune neuromuscular disease | |
CN115243774B (en) | Pharmaceutical composition containing amlodipine, chlorthalidone and amiloride | |
Han et al. | Safety and efficacy of fimasartan with essential hypertension patients in real world clinical practice: data from a post marketing surveillance in Korea | |
US20230338351A1 (en) | Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment | |
TW202416992A (en) | Dosage regimens of estrogen receptor degraders | |
CN116585334A (en) | Application of paeoniflorin in preparation of medicines for treating inflammatory bowel disease | |
AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
CN118338901A (en) | CDK4 inhibitors for the treatment of cancer | |
WO2020247706A1 (en) | Methods of treating and/or preventing psoriasis | |
MYLAN-SUMATRIPTAN | 5-HT1 Receptor Agonist | |
TW202010496A (en) | Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080039242.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10763456 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20127004156 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012527447 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13394373 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2010763456 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010763456 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2729/DELNP/2012 Country of ref document: IN |